← U.S. Physical Therapy overview

U.S. Physical Therapy vs The Ensign: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

U.S. Physical Therapy, Inc. (USPH)

Q3 2026
▲2

USPH grows visits and buys clinics, but costs squeeze profit

  • Record visits and rates, but profit squeezed by costs USPH's Q2 revenue rose 8.5% to $214.1 million, with record per-visit rates and all-time-high visits per clinic. But net income fell to $9.9 million from $12.4 million as employee health costs and new hiring ate into margins. Growth is real, yet profit is shrinking — that tug-of-war is what moves the stock.

    It is the core new earnings result and explains the mixed pressure on USPH's price.

  • Hospital alliances open a new growth path Management is pushing partnerships with hospital systems like NYU Langone, now 60 New York locations, which bring steadier patient volumes and flat, predictable per-visit payments. The injury-prevention unit has grown to about $120 million in revenue with roughly double the margins of the core therapy business.

    It is the newest strategic driver management is betting on for future growth.

  • New permanent CFO ends leadership uncertainty USPH named Nchacha Etta, a former Omnicell and Johnson & Johnson Vision finance chief, as CFO effective September 1, ending the interim period that began in April. A settled finance leadership is a modest positive, though it does not change the underlying business.

    It is a genuinely new company event that removes an overhang on the stock.

  • Acquisitions keep growing, but debt and cash tighten USPH closed three deals this year for $37.6 million, adding about $27 million of annual revenue, and reaffirmed full-year EBITDA guidance of $102–106 million. But cash fell to $24.9 million while credit borrowings rose to $221 million, so the buying spree is being funded with debt.

    It shows the growth engine and its financing cost, a real counterweight for investors.

August 2026
▲2

USPH grows visits and buys clinics, but costs squeeze profit

  • Record visits and rates, but profit squeezed by costs USPH's Q2 revenue rose 8.5% to $214.1 million, with record per-visit rates and all-time-high visits per clinic. But net income fell to $9.9 million from $12.4 million as employee health costs and new hiring ate into margins. Growth is real, yet profit is shrinking — that tug-of-war is what moves the stock.

    It is the core new earnings result and explains the mixed pressure on USPH's price.

  • Hospital alliances open a new growth path Management is pushing partnerships with hospital systems like NYU Langone, now 60 New York locations, which bring steadier patient volumes and flat, predictable per-visit payments. The injury-prevention unit has grown to about $120 million in revenue with roughly double the margins of the core therapy business.

    It is the newest strategic driver management is betting on for future growth.

  • New permanent CFO ends leadership uncertainty USPH named Nchacha Etta, a former Omnicell and Johnson & Johnson Vision finance chief, as CFO effective September 1, ending the interim period that began in April. A settled finance leadership is a modest positive, though it does not change the underlying business.

    It is a genuinely new company event that removes an overhang on the stock.

  • Acquisitions keep growing, but debt and cash tighten USPH closed three deals this year for $37.6 million, adding about $27 million of annual revenue, and reaffirmed full-year EBITDA guidance of $102–106 million. But cash fell to $24.9 million while credit borrowings rose to $221 million, so the buying spree is being funded with debt.

    It shows the growth engine and its financing cost, a real counterweight for investors.

Latest
▲2

USPH grows visits and buys clinics, but costs squeeze profit

  • Record visits and rates, but profit squeezed by costs USPH's Q2 revenue rose 8.5% to $214.1 million, with record per-visit rates and all-time-high visits per clinic. But net income fell to $9.9 million from $12.4 million as employee health costs and new hiring ate into margins. Growth is real, yet profit is shrinking — that tug-of-war is what moves the stock.

    It is the core new earnings result and explains the mixed pressure on USPH's price.

  • Hospital alliances open a new growth path Management is pushing partnerships with hospital systems like NYU Langone, now 60 New York locations, which bring steadier patient volumes and flat, predictable per-visit payments. The injury-prevention unit has grown to about $120 million in revenue with roughly double the margins of the core therapy business.

    It is the newest strategic driver management is betting on for future growth.

  • New permanent CFO ends leadership uncertainty USPH named Nchacha Etta, a former Omnicell and Johnson & Johnson Vision finance chief, as CFO effective September 1, ending the interim period that began in April. A settled finance leadership is a modest positive, though it does not change the underlying business.

    It is a genuinely new company event that removes an overhang on the stock.

  • Acquisitions keep growing, but debt and cash tighten USPH closed three deals this year for $37.6 million, adding about $27 million of annual revenue, and reaffirmed full-year EBITDA guidance of $102–106 million. But cash fell to $24.9 million while credit borrowings rose to $221 million, so the buying spree is being funded with debt.

    It shows the growth engine and its financing cost, a real counterweight for investors.

The Ensign Group Inc (ENSG)

Q3 2026
▲2▼2

Ensign hit by fraud investigations but raises guidance on strong Q2

  • Securities fraud investigations pile up Multiple law firms (Bleichmar Fonti, Pomerantz, Robbins Geller, Rosen, Hagens Berman) launched investigations into Ensign for potential securities fraud, alleging it misled investors about care quality, regulatory compliance, and growth. This creates legal overhang and could lead to fines or class actions, pressuring the stock.

    These investigations are new this period and directly threaten ENSG's legal and financial standing.

  • Short-seller reports allege understaffing and fraud Hunterbrook and Muddy Waters published reports accusing Ensign of understaffing facilities, gaming quality metrics, and routing government payments to affiliates, potentially violating Medicare/Medicaid rules. The stock fell over 11% in two days, wiping out $500 million in market value, as investors fear billions in liabilities.

    These reports are the root cause of the investigations and the sharp stock drop, making them a key new driver.

  • Strong Q2 results and raised 2026 guidance Ensign reported Q2 revenue of $1.44 billion (up 17.3%) and adjusted EPS of $1.92, then raised full-year guidance to $7.75–$7.85 EPS and $5.87–$5.92 billion revenue. Same-facility occupancy hit 84.1% and skilled mix revenue grew 10.1%, showing robust demand and operational strength.

    This is fresh positive news that counters the negative narrative and directly boosts investor confidence.

  • Continued expansion with 20 new operations Ensign added 20 new healthcare operations in the quarter, bringing its portfolio to 398 facilities across 17 states. This growth demonstrates the company's ability to execute its acquisition strategy despite the negative headlines, supporting future revenue and earnings.

    This new expansion detail shows operational momentum and is part of the Q2 update that investors may weigh against the fraud allegations.

July 2026
▲2▼2

Ensign hit by fraud investigations but raises guidance on strong Q2

  • Securities fraud investigations pile up Multiple law firms (Bleichmar Fonti, Pomerantz, Robbins Geller, Rosen, Hagens Berman) launched investigations into Ensign for potential securities fraud, alleging it misled investors about care quality, regulatory compliance, and growth. This creates legal overhang and could lead to fines or class actions, pressuring the stock.

    These investigations are new this period and directly threaten ENSG's legal and financial standing.

  • Short-seller reports allege understaffing and fraud Hunterbrook and Muddy Waters published reports accusing Ensign of understaffing facilities, gaming quality metrics, and routing government payments to affiliates, potentially violating Medicare/Medicaid rules. The stock fell over 11% in two days, wiping out $500 million in market value, as investors fear billions in liabilities.

    These reports are the root cause of the investigations and the sharp stock drop, making them a key new driver.

  • Strong Q2 results and raised 2026 guidance Ensign reported Q2 revenue of $1.44 billion (up 17.3%) and adjusted EPS of $1.92, then raised full-year guidance to $7.75–$7.85 EPS and $5.87–$5.92 billion revenue. Same-facility occupancy hit 84.1% and skilled mix revenue grew 10.1%, showing robust demand and operational strength.

    This is fresh positive news that counters the negative narrative and directly boosts investor confidence.

  • Continued expansion with 20 new operations Ensign added 20 new healthcare operations in the quarter, bringing its portfolio to 398 facilities across 17 states. This growth demonstrates the company's ability to execute its acquisition strategy despite the negative headlines, supporting future revenue and earnings.

    This new expansion detail shows operational momentum and is part of the Q2 update that investors may weigh against the fraud allegations.

Latest
▲2▼2

Ensign hit by fraud investigations but raises guidance on strong Q2

  • Securities fraud investigations pile up Multiple law firms (Bleichmar Fonti, Pomerantz, Robbins Geller, Rosen, Hagens Berman) launched investigations into Ensign for potential securities fraud, alleging it misled investors about care quality, regulatory compliance, and growth. This creates legal overhang and could lead to fines or class actions, pressuring the stock.

    These investigations are new this period and directly threaten ENSG's legal and financial standing.

  • Short-seller reports allege understaffing and fraud Hunterbrook and Muddy Waters published reports accusing Ensign of understaffing facilities, gaming quality metrics, and routing government payments to affiliates, potentially violating Medicare/Medicaid rules. The stock fell over 11% in two days, wiping out $500 million in market value, as investors fear billions in liabilities.

    These reports are the root cause of the investigations and the sharp stock drop, making them a key new driver.

  • Strong Q2 results and raised 2026 guidance Ensign reported Q2 revenue of $1.44 billion (up 17.3%) and adjusted EPS of $1.92, then raised full-year guidance to $7.75–$7.85 EPS and $5.87–$5.92 billion revenue. Same-facility occupancy hit 84.1% and skilled mix revenue grew 10.1%, showing robust demand and operational strength.

    This is fresh positive news that counters the negative narrative and directly boosts investor confidence.

  • Continued expansion with 20 new operations Ensign added 20 new healthcare operations in the quarter, bringing its portfolio to 398 facilities across 17 states. This growth demonstrates the company's ability to execute its acquisition strategy despite the negative headlines, supporting future revenue and earnings.

    This new expansion detail shows operational momentum and is part of the Q2 update that investors may weigh against the fraud allegations.

Q2 2026
▼2▲1

Short-seller fraud claims trigger law firm probes; strong Q1 growth continues

  • Law firm investigations into short-seller fraud claims Multiple law firms (Rosen, Bleichmar, Pomerantz, Kessler Topaz, Robbins Geller) are investigating Ensign for securities fraud after short sellers Hunterbrook and Muddy Waters alleged understaffing, fake compliance, and misleading quality metrics. These probes raise legal costs and regulatory risk, weighing on the stock.

    This is the main new negative force this period, with multiple investigations announced.

  • Strong Q1 2026 growth and acquisition momentum Ensign added 22 operations in Q1 2026, bringing total acquisitions to 71 since 2025. Revenue rose 18.4% to $1.39 billion, adjusted EPS hit $1.85, and same-store occupancy reached a record 84.3%. This shows the core business is still expanding profitably.

    This is new positive fundamental data that contrasts with the negative legal news.

  • Short-seller reports wipe out $500M in market value Hunterbrook and Muddy Waters reports since June 7 have erased over $500 million in market cap. Muddy Waters alleged fake administrator licenses at 57 facilities, potentially violating the False Claims Act. This creates uncertainty and selling pressure.

    This is the core negative event driving the stock down, with specific financial impact.

June 2026
▼2▲1

Short-seller fraud claims trigger law firm probes; strong Q1 growth continues

  • Law firm investigations into short-seller fraud claims Multiple law firms (Rosen, Bleichmar, Pomerantz, Kessler Topaz, Robbins Geller) are investigating Ensign for securities fraud after short sellers Hunterbrook and Muddy Waters alleged understaffing, fake compliance, and misleading quality metrics. These probes raise legal costs and regulatory risk, weighing on the stock.

    This is the main new negative force this period, with multiple investigations announced.

  • Strong Q1 2026 growth and acquisition momentum Ensign added 22 operations in Q1 2026, bringing total acquisitions to 71 since 2025. Revenue rose 18.4% to $1.39 billion, adjusted EPS hit $1.85, and same-store occupancy reached a record 84.3%. This shows the core business is still expanding profitably.

    This is new positive fundamental data that contrasts with the negative legal news.

  • Short-seller reports wipe out $500M in market value Hunterbrook and Muddy Waters reports since June 7 have erased over $500 million in market cap. Muddy Waters alleged fake administrator licenses at 57 facilities, potentially violating the False Claims Act. This creates uncertainty and selling pressure.

    This is the core negative event driving the stock down, with specific financial impact.

▼2▲1

Short-seller fraud claims trigger law firm probes; strong Q1 growth continues

  • Law firm investigations into short-seller fraud claims Multiple law firms (Rosen, Bleichmar, Pomerantz, Kessler Topaz, Robbins Geller) are investigating Ensign for securities fraud after short sellers Hunterbrook and Muddy Waters alleged understaffing, fake compliance, and misleading quality metrics. These probes raise legal costs and regulatory risk, weighing on the stock.

    This is the main new negative force this period, with multiple investigations announced.

  • Strong Q1 2026 growth and acquisition momentum Ensign added 22 operations in Q1 2026, bringing total acquisitions to 71 since 2025. Revenue rose 18.4% to $1.39 billion, adjusted EPS hit $1.85, and same-store occupancy reached a record 84.3%. This shows the core business is still expanding profitably.

    This is new positive fundamental data that contrasts with the negative legal news.

  • Short-seller reports wipe out $500M in market value Hunterbrook and Muddy Waters reports since June 7 have erased over $500 million in market cap. Muddy Waters alleged fake administrator licenses at 57 facilities, potentially violating the False Claims Act. This creates uncertainty and selling pressure.

    This is the core negative event driving the stock down, with specific financial impact.